- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2016–2019 · grant · BCRP
Targeting MCL-1 with Unique Peptide Inhibitors Delivered Intracellularly Using a Novel Nanoparticle Formulation
Donald Kufe · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2023 · research · R35
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
A. Thomas Look · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2017 · career development · K99
Roles of tumor-derived PTHrP in skeletal muscle atrophy and cancer cachexia
Serkan Kir · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2030 · research · R35
The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016 · career development · K08
The role of oxidative stress in the pathogenesis of Reticular Dysgenesis and the therapeutic potential of antioxidants
Katja Gabriele Weinacht · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · training · T32
Cancer Immunology Training Grant
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · research · R00
Lineage-based inference of cell state transition dynamics in development and disease
Sahand Hormoz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Immunogenomic analytical approaches for research and clinical applications
Sachet Ashok Shukla · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · career development · K00
The role of CMTR2 in Lung Cancer
Alena Yermalovich · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · fellowship · F31
Dissecting the Mitochondrial Translocation Mechanism of Anti-Apoptotic BCL-w
Edward Paul Harvey · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2017 · career development · K99
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
Chun-Wei David Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Neuroimmune mechanisms of depression in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2024 · research · R35
Phosphoinositides and Cancer Metabolism
Lewis C. Cantley · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016 · award
Macrophage-tumor cell crosstalk via IL8-CXCR1/2 in prostate cancer
Dinesh Thapa · Dana-Farber Cancer Institute · funded by American Cancer Society
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Novel functions of D-type and E-type cyclins in normal and in cancer cells
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
New Paradigms for Targeting Truncal Driver Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Immunogenomic analytical approaches for research and clinical applications
Sachet Ashok Shukla · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
Elucidating KRAS-specific vulnerabilities in pancreatic cancer
Mandar Deepak Muzumdar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016 · research · AACR-Bayer Innovation and Discovery Grants
Enhanced Anti-Cancer Immunotherapy through Targeted STAT3 Inhibition
David A. Frank · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2016 · career development · Young Investigator Award
Extracellular matrix modulation of therapeutic sensitivity in pancreatic ductal adenocarcinoma
Srivatsan Raghavan · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · career development · Young Investigator Award
Exploring the Nonsense-mediated Decay Pathway as a Novel Cancer Vulnerability
Srinivas Viswanathan · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · career development · Young Investigator Award
The Role of Hematopoietic Stem Cell Mutations in the Pathogenesis of Therapy-Related Myeloid Neoplasm Following Treatment for non-Hodgkin lymphoma
Christopher Gibson · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · career development · Young Investigator Award
Patient and Parent Understanding and Experiences with Genomic Tumor Profiling (GTP) in Pediatric Oncology
Jonathan Marron · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · career development · Young Investigator Award
Investigation of FOXO3-dependent transcriptional activity as a therapeutic target in triple-negative breast cancer (TNBC)
Sameer Chopra · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · fellowship · AACR-Bristol-Myers Squibb Fellowship in Translational Immuno- oncology
Dissecting mechanisms of PD-1 blockade with single-cell RNA-sequencing
Brian Christopher Miller · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2016 · career development · Young Investigator Award
Genomic complexity and resistance mechanisms in non-small cell lung cancer
Amanda Redig · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · research · AACR-Takeda Oncology NextGen Grant for Transformative Cancer Research
Overcoming resistance to combined ER and CDK4/6 inhibition in breast cancer
Nikhil Wagle · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2016 · research · AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research
Mechanisms of enhancer rewiring in drug resistant T-ALL
Birgit Knoechel · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2016 · career development · Young Investigator Award
PD-L2, chronic inflammation and PD-1 blockade in esophageal adenocarcinoma.
Sarah Derks · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2016 · fellowship · AACR Basic Cancer Research Fellowship
Mitochondrial perturbations as a novel approach to personalized therapy
Shruti Bhatt · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2016–2031 · research · R35
Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism
Lewis C. Cantley · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2030 · research · R35
The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2027 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
